Disseminated Strongyloides stercoralis infection in HTLV-1-associated adult T-cell leukemia/lymphoma

Acta Haematologica

Volumn 126, Issue 2, 2011, Pages 63-67

  Stewart, Donn M ^a   Ramanathan, Roshan ^b   Mahanty, Siddhartha ^b   Fedorko, Daniel P ^c   Janik, John E ^a   Morris, John C ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Adult T cell leukemia; Alemtuzumab; Corticosteroid; Disseminated Strongyloides; HTLV 1; Human T cell lymphotropic virus type 1

Indexed keywords

ACICLOVIR; ALBENDAZOLE; ALEMTUZUMAB; AMPICILLIN; DACLIZUMAB; DEXAMETHASONE; IVERMECTIN; MEROPENEM; PREDNISOLONE ACETATE; VANCOMYCIN;

ABDOMINAL DISCOMFORT; ADULT; ARTICLE; BARBADOS; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; DIARRHEA; DIZZINESS; DRUG DOSE INCREASE; DRUG WITHDRAWAL; DYSPNEA; FEMALE; GASTROJEJUNOSTOMY; HEPATOSPLENOMEGALY; HUMAN; HUMAN T CELL LEUKEMIA VIRUS 1; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; RASH; STRONGYLOIDIASIS; VITREOUS BIOPSY; VITREOUS DISEASE; VOMITING; WEIGHT REDUCTION;

ANIMALS; FEMALE; HTLV-I INFECTIONS; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOMA, T-CELL; MIDDLE AGED; OPPORTUNISTIC INFECTIONS; RECURRENCE; STRONGYLOIDES STERCORALIS; STRONGYLOIDIASIS; TREATMENT OUTCOME;

EID: 79953674826     PISSN: 00015792     EISSN: 14219662     Source Type: Journal    
DOI: 10.1159/000324799     Document Type: Article

References (33)

1. Tsukasaki K, Hermine O, Bazarbachi A, Ratner L, Ramos JC, Harrington W Jr., O'Mahony D, Janik JE, Bittencourt AL, Taylor GP, Yamaguchi K, Utsunomiya A, Tobinai K, Watanabe T: Definition, prognostic factors, treatment, and response criteria of adult Tcell leukemia-lymphoma: A proposal from an international consensus meeting. J Clin Oncol 2009; 27: 453-459.
2. Carvalho EM, Da Fonseca Porto A: Epidemiological and clinical interaction between HTLV-1 and Strongyloides stercoralis Parasite Immunol 2004; 26: 487-497. (Pubitemid 40461165)
3. Brodine SK, Thomas A, Huang R, Harbertson J, Mehta S, Leake J, Nutman T, Moser K, Wolf J, Ramanathan R, Burbelo P, Nou J, Wilkins P, Reed SL: Community-based parasitic screening and treatment of Sudanese refugees: Application and assessment of Centers for Disease Control guidelines. Am J Trop Med Hyg 2009; 80: 425-430.
4. Dawson-Hahn EE, Greenberg SL, Domachowske JB, Olson BG: Eosinophilia and the seroprevalence of schistosomiasis and strongyloidiasis in newly arrived pediatric refugees: An examination of Centers for Disease Control and Prevention screening guidelines. J Pediatr 2010; 156: 1016-1018.
5. Ramanathan R, Nutman T: Strongyloides stercoralis infection in the immunocompromised host. Curr Infect Dis Rep 2008; 10: 105-110.
6. Salluh JI, Bozza FA, Pinto TS, Toscano L, Weller PF, Soares M: Cutaneous periumbilical purpura in disseminated strongyloidiasis in cancer patients: A pathognomonic feature of potentially lethal disease? Braz J Infect Dis 2005; 9: 419-424. (Pubitemid 43130810)
7. Montes M, Sanchez C, Verdonck K, Lake JE, Gonzalez E, Lopez G, Terashima A, Nolan T, Lewis DE, Gotuzzo E, White AC Jr.: Regulatory T-cell expansion in HTLV-1 and strongyloidiasis co-infection is associated with reduced IL-5 responses to Strongyloides stercoralis antigen. PLoS Negl Trop Dis 2009; 3:e456.
8. Nakada K, Yamaguchi K, Furugen S, Nakasone T, Nakasone K, Oshiro Y, Kohakura M, Hinuma Y, Seiki M, Yoshida M, Matutes E, Catovsky D, Ishii T, Takatsuki K: Monoclonal integration of HTLV-1 proviral DNA in patients with strongyloidiasis. Int J Cancer 1987; 40: 145-148. (Pubitemid 17130826)
9. Satoh M, Toma H, Sugahara K, Etoh K, Shiroma Y, Kiyuna S, Takara M, Matsuoka M, Yamaguchi K, Nakada K, Fujita K, Kojima S, Hori E, Tanaka Y, Kamihira S, Sato Y, Watanabe T: Involvement of IL-2/IL-2R system activation by parasite antigen in polyclonal expansion of CD4+25+ HTLV-1-infected T cells in human carriers of both HTLV-1 and S. stercoralis Oncogene 2002; 21: 2466-2475. (Pubitemid 34438099)
10. Ratner L, Grant C, Zimmerman B, Fritz J, Weil G, Denes A, Suresh R, Campbell N, Jacobson S, Lairmore M: Effect of treatment of Strongyloides infection on HTLV-1 expression in a patient with adult T-cell leukemia. Am J Hematol 2007; 82: 929-931. (Pubitemid 47502701)
11. Agape P, Copin MC, Cavrois M, Panelatti G, Plumelle Y, Ossondo-Landeau M, Quist D, Grossat N, Gosselin B, Fenaux P, Wattel E: Implication of HTLV-I infection, strongyloidiasis, and P53 overexpression in the development, response to treatment, and evolution of non-Hodgkin's lymphomas in an endemic area (Martinique, French West Indies). J Acquir Immune Defic Syndr Hum Retrovirol 1999; 20: 394-402. (Pubitemid 29143035)
12. Porto AF, Santos SB, Muniz AL, Basilio V, Rodrigues W Jr., Neva FA, Dutra WO, Gollob KJ, Jacobson S, Carvalho EM: Helminthic infection down-regulates type 1 immune responses in human T-cell lymphotropic virus type 1 (HTLV-1) carriers and is more prevalent in HTLV-1 carriers than in patients with HTLV-1-associated myelopathy/tropical spastic paraparesis. J Infect Dis 2005; 191: 612-618. (Pubitemid 40216678)
13. Thomas MC, Costello SA: Disseminated strongyloidiasis arising from a single dose of dexamethasone before stereotactic radiosurgery. Int J Clin Pract 1998; 52: 520-521. (Pubitemid 28512841)
14. Qazilbash MH, Ueno NT, Hosing C, De Lima M, Cortes J, Massaro A, Rivera Z, Deavers M, Adachi JA, Champlin RE: Strongyloidiasis after unrelated nonmyeloablative allogeneic stem cell transplantation. Bone Marrow Transplant 2006; 38: 393-394.
15. Keiser PB, Nutman TB: Strongyloides stercoralis in the immunocompromised population. Clin Microbiol Rev 2004; 17: 208-217. (Pubitemid 38120934)
16. Genta RM: Dysregulation of strongyloidiasis: A new hypothesis. Clin Microbiol Rev 1992; 5: 345-355.
17. Siddiqui AA, Berk SL: Diagnosis of Strongyloides stercoralis infection. Clin Infect Dis 2001; 33: 1040-1047. (Pubitemid 32907108)
18. Pelletier LL Jr.: Chronic strongyloidiasis in World War II Far East ex-prisoners of war. Am J Trop Med Hyg 1984; 33: 55-61. (Pubitemid 14190440)
19. Hirata T, Nakamura H, Kinjo N, Hokama A, Kinjo F, Yamane N, Fujita J: Increased detection rate of Strongyloides stercoralis by repeated stool examinations using the agar plate culture method. Am J Trop Med Hyg 2007; 77: 683-684. (Pubitemid 351844292)
20. Goka AK, Rolston DD, Mathan VI, Farthing MJ: Diagnosis of Strongyloides and hookworm infections: Comparison of faecal and duodenal fluid microscopy. Trans R Soc Trop Med Hyg 1990; 84: 829-831.
21. Loutfy MR, Wilson M, Keystone JS, Kain KC: Serology and eosinophil count in the diagnosis and management of strongyloidiasis in a non-endemic area. Am J Trop Med Hyg 2002; 66: 749-752. (Pubitemid 35001049)
22. Schaffel R, Nucci M, Carvalho E, Braga M, Almeida L, Portugal R, Pulcheri W: The value of an immunoenzymatic test (enzymelinked immunosorbent assay) for the diagnosis of strongyloidiasis in patients immunosuppressed by hematologic malignancies. Am J Trop Med Hyg 2001; 65: 346-350. (Pubitemid 33022024)
23. Ramanathan R, Burbelo PD, Groot S, Iadarola MJ, Neva FA, Nutman TB: A luciferase immunoprecipitation systems assay enhances the sensitivity and specificity of diagnosis of Strongyloides stercoralis infection. J Infect Dis 2008; 198: 444-451.
24. Gann PH, Neva FA, Gam AA: A randomized trial of single- and two-dose ivermectin versus thiabendazole for treatment of strongyloidiasis. J Infect Dis 1994; 169: 1076-1079. (Pubitemid 24303229)
25. Marti H, Haji HJ, Savioli L, Chwaya HM, Mgeni AF, Ameir JS, Hatz C: A comparative trial of a single-dose ivermectin versus three days of albendazole for treatment of Strongyloides stercoralis and other soil-transmitted helminth infections in children. Am J Trop Med Hyg 1996; 55: 477-481. (Pubitemid 26392708)
26. Twum-Danso NA: Loa loa encephalopathy temporally related to ivermectin administration reported from onchocerciasis mass treatment programs from 1989 to 2001: Implications for the future. Filaria J 2003; 2 (suppl 1):S7.
27. Karunajeewa H, Kelly H, Leslie D, Leydon J, Saykao P, Biggs BA: Parasite-specific IgG response and peripheral blood eosinophil count following albendazole treatment for presumed chronic strongyloidiasis. J Travel Med 2006; 13: 84-91.
28. Page WA, Dempsey K, McCarthy JS: Utility of serological follow-up of chronic strongyloidiasis after anthelminthic chemotherapy. Trans R Soc Trop Med Hyg 2006; 100: 1056-1062. (Pubitemid 44309207)
29. Turner SA, Maclean JD, Fleckenstein L, Greenaway C: Parenteral administration of ivermectin in a patient with disseminated strongyloidiasis. Am J Trop Med Hyg 2005; 73: 911-914. (Pubitemid 41688467)
30. Boken DJ, Leoni PA, Preheim LC: Treatment of Strongyloides stercoralis hyperinfection syndrome with thiabendazole administered per rectum. Clin Infect Dis 1993; 16: 123-126. (Pubitemid 23007241)
31. Roxby AC, Gottlieb GS, Limaye AP: Strongyloidiasis in transplant patients. Clin Infect Dis 2009; 49: 1411-1423.
32. Santiago M, Leitao B: Prevention of Strongyloides hyperinfection syndrome: A rheumatological point of view. Eur J Intern Med 2009; 20: 744-748.
33. Peters L, McCarthy AE, Faught C: Secondary Strongyloides stercoralis prophylaxis in patients with human T-cell lymphotropic virus type 1 infection: Report of two cases. Int J Infect Dis 2009; 13:e501-e503.